
Provectus Biopharmaceuticals, Inc. – OTC:PVCT
Provectus Biopharmaceuticals stock price today
Provectus Biopharmaceuticals stock price monthly change
Provectus Biopharmaceuticals stock price quarterly change
Provectus Biopharmaceuticals stock price yearly change
Provectus Biopharmaceuticals key metrics
Market Cap | 50.34M |
Enterprise value | 67.09M |
P/E | -15.48 |
EV/Sales | N/A |
EV/EBITDA | -12.39 |
Price/Sales | N/A |
Price/Book | -10.42 |
PEG ratio | -1.03 |
EPS | N/A |
Revenue | 590.75K |
EBITDA | -2.42M |
Income | -2.77M |
Revenue Q/Q | 16.11% |
Revenue Y/Y | -41.30% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -411.11% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeProvectus Biopharmaceuticals stock price history
Provectus Biopharmaceuticals stock forecast
Provectus Biopharmaceuticals financial statements
Jun 2023 | 161.84K | -835.06K | -515.97% |
---|---|---|---|
Sep 2023 | 69.73K | -775.83K | -1112.59% |
Dec 2023 | 121.11K | -663.41K | -547.78% |
Mar 2024 | 238.07K | -504.04K | -211.72% |
Jun 2023 | 1686603 | 8.98M | 532.64% |
---|---|---|---|
Sep 2023 | 1690093 | 9.20M | 544.9% |
Dec 2023 | 1448843 | 9.04M | 624.1% |
Mar 2024 | 1078991 | 8.52M | 790.43% |
Jun 2023 | -617.78K | 0 | 656.44K |
---|---|---|---|
Sep 2023 | -768.87K | -49.99K | 817.85K |
Dec 2023 | -561.21K | 49.99K | 201.55K |
Mar 2024 | -1.04M | 0 | 781.09K |
Provectus Biopharmaceuticals alternative data
Aug 2023 | 4 |
---|---|
Sep 2023 | 4 |
Oct 2023 | 4 |
Nov 2023 | 4 |
Dec 2023 | 4 |
Jan 2024 | 4 |
Feb 2024 | 4 |
Mar 2024 | 4 |
Apr 2024 | 4 |
May 2024 | 4 |
Jun 2024 | 4 |
Jul 2024 | 4 |
Provectus Biopharmaceuticals other data
Period | Buy | Sel |
---|---|---|
Nov 2024 | 80365 | 0 |
Quarter | Transcript |
---|---|
Q1 2024 22 Feb 2024 | Q1 2024 Earnings Call Transcript |
-
What's the price of Provectus Biopharmaceuticals stock today?
One share of Provectus Biopharmaceuticals stock can currently be purchased for approximately $0.08.
-
When is Provectus Biopharmaceuticals's next earnings date?
Unfortunately, Provectus Biopharmaceuticals's (PVCT) next earnings date is currently unknown.
-
Does Provectus Biopharmaceuticals pay dividends?
No, Provectus Biopharmaceuticals does not pay dividends.
-
How much money does Provectus Biopharmaceuticals make?
Provectus Biopharmaceuticals has a market capitalization of 50.34M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 43.61% to 557.71K US dollars.
-
What is Provectus Biopharmaceuticals's stock symbol?
Provectus Biopharmaceuticals, Inc. is traded on the OTC under the ticker symbol "PVCT".
-
What is Provectus Biopharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Provectus Biopharmaceuticals?
Shares of Provectus Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Provectus Biopharmaceuticals have?
As Jul 2024, Provectus Biopharmaceuticals employs 4 workers.
-
When Provectus Biopharmaceuticals went public?
Provectus Biopharmaceuticals, Inc. is publicly traded company for more then 25 years since IPO on 7 Jun 2000.
-
What is Provectus Biopharmaceuticals's official website?
The official website for Provectus Biopharmaceuticals is provectusbio.com.
-
Where are Provectus Biopharmaceuticals's headquarters?
Provectus Biopharmaceuticals is headquartered at 10025 Investment Drive, Knoxville, TN.
-
How can i contact Provectus Biopharmaceuticals?
Provectus Biopharmaceuticals's mailing address is 10025 Investment Drive, Knoxville, TN and company can be reached via phone at +86 65945999.
Provectus Biopharmaceuticals company profile:

Provectus Biopharmaceuticals, Inc.
provectusbio.comOTC
4
Biotechnology
Healthcare
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal cancer metastatic to the liver; neuroendocrine tumors metastatic to the liver; uveal melanoma metastatic to the liver; and pediatric solid tumor cancers, such as neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. The company is also developing oral formulations of current good manufacturing practice rose bengal sodium (cGMP RBS) for the treatment of adult solid tumor cancers, such as head and neck, breast, testicular, and colorectal cancers; pediatric blood cancers, including leukemia; coronavirus, an acute respiratory syndrome; multi-drug resistant bacteria, such as gram-negative bacteria; and for eye diseases, including infectious keratitis. In addition, it develops PH-10, an investigational immuno-dermatology agent for the treatment of inflammatory dermatoses, such as psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was incorporated in 2002 and is based in Knoxville, Tennessee.
Knoxville, TN 37932
CIK: 0000315545
ISIN: US74373P1084
CUSIP: 74373P108